Pharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) announced Tuesday that it is acquiring RayzeBio (NASDAQ: RYZB) for $4.1 billion, strengthening its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List Management Comments Mergers and Acquisitions

Karuna Therapeutics cut by analysts following news of Bristol-Myers Squibb acquisitionDecember 26, 2023 11:14 AM Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioDecember 26, 2023 7:13 AM RayzeBio (RYZB) 30-day option implied volatility near upper end of rangeDecember 26, 2023 7:12 AM Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy pushDecember 26, 2023 7:08 AM RayzeBio (RYZB) to Resume Trading at 7:30 a.m. December 26, 2023 7:05 AM Bristol-Myers Squibb (BMY) Announces Acquisition of RayzeBio (RYZB) for $62.50 Per Share, $4.1 BillionDecember 26, 2023 7:00 AM  Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioDecember 26, 2023 6:59 AM RayzeBio (RYZB) Halted, News PendingDecember 26, 2023 6:56 AM